Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Символ: 002693.SZ
SHZ
5.26
CNYПазарна цена днес
2335.5868
Съотношение P/E
46.7117
Коефициент PEG
2.18B
MRK Cap
- 0.00%
Доходност на DIV
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 291.41 | 146 | 77 | 100 | ||||||||||||||
balance-sheet.row.short-term-investments | 223.27 | 133.8 | 55.4 | 94.3 | ||||||||||||||
balance-sheet.row.net-receivables | 97.01 | 41 | 33.1 | 44.6 | ||||||||||||||
balance-sheet.row.inventory | 306.61 | 65.4 | 55.2 | 52.8 | ||||||||||||||
balance-sheet.row.other-current-assets | 63.21 | 0 | 0.1 | 0 | ||||||||||||||
balance-sheet.row.total-current-assets | 721.6 | 252.4 | 165.4 | 197.5 | ||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1823.92 | 471.8 | 504.7 | 541 | ||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.intangible-assets | 463.52 | 164.9 | 156.9 | 134.4 | ||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 463.52 | 164.9 | 156.9 | 134.4 | ||||||||||||||
balance-sheet.row.long-term-investments | 44.81 | 8.8 | 17.3 | 25.9 | ||||||||||||||
balance-sheet.row.tax-assets | 1.73 | 1 | 1 | 0.7 | ||||||||||||||
balance-sheet.row.other-non-current-assets | 310.74 | 12.2 | 9.1 | 8.3 | ||||||||||||||
balance-sheet.row.total-non-current-assets | 2644.71 | 658.6 | 689.1 | 710.2 | ||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-assets | 3366.32 | 911 | 854.6 | 907.7 | ||||||||||||||
balance-sheet.row.account-payables | 61.58 | 15.5 | 17.2 | 15.4 | ||||||||||||||
balance-sheet.row.short-term-debt | 388.3 | 205.3 | 0.3 | 55.7 | ||||||||||||||
balance-sheet.row.tax-payables | 7.8 | 12.8 | 7.2 | 6.3 | ||||||||||||||
balance-sheet.row.long-term-debt-total | 290.02 | 0 | 167 | 167 | ||||||||||||||
Deferred Revenue Non Current | 15.36 | 7.6 | 8.9 | 10.3 | ||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 6 | - | - | - | ||||||||||||||
balance-sheet.row.other-current-liab | 221.32 | 73.6 | 1.8 | 1.5 | ||||||||||||||
balance-sheet.row.total-non-current-liabilities | 332.55 | 10.7 | 179.4 | 180 | ||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-liab | 1177.06 | 330.1 | 287.8 | 309.4 | ||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.common-stock | 1666.33 | 414.7 | 412 | 405 | ||||||||||||||
balance-sheet.row.retained-earnings | -1219.08 | -296.2 | -305.2 | -284.6 | ||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 501.27 | 87.2 | 82.2 | 86 | ||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1044.52 | 307.9 | 292.9 | 286.5 | ||||||||||||||
balance-sheet.row.total-stockholders-equity | 1993.04 | 513.5 | 481.8 | 492.9 | ||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3366.32 | 911 | 854.6 | 907.7 | ||||||||||||||
balance-sheet.row.minority-interest | 196.22 | 67.4 | 84.9 | 105.4 | ||||||||||||||
balance-sheet.row.total-equity | 2189.26 | 580.9 | 566.8 | 598.3 | ||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3366.32 | - | - | - | ||||||||||||||
Total Investments | 243.27 | 133.8 | 55.4 | 94.3 | ||||||||||||||
balance-sheet.row.total-debt | 678.32 | 205.3 | 167.3 | 222.7 | ||||||||||||||
balance-sheet.row.net-debt | 610.18 | 193.1 | 145.6 | 216.9 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -63.99 | -8.5 | -40.8 | -79.9 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 40.38 | 57.5 | 54.3 | 57.1 | ||||||||||||||
cash-flows.row.deferred-income-tax | -3.82 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.stock-based-compensation | 1.42 | 6.9 | 7.2 | -1.2 | ||||||||||||||
cash-flows.row.change-in-working-capital | -10.62 | -4.5 | 14.9 | -12.2 | ||||||||||||||
cash-flows.row.account-receivables | 4.99 | -13.8 | 5.4 | 39.8 | ||||||||||||||
cash-flows.row.inventory | -12.45 | -9.9 | -4.8 | -4.3 | ||||||||||||||
cash-flows.row.account-payables | 0 | 19.6 | 13.8 | -48.9 | ||||||||||||||
cash-flows.row.other-working-capital | -3.17 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | 45.94 | -25.8 | -12.5 | 24.5 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 7.88 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -50.56 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.acquisitions-net | 14.27 | 27 | 21.7 | 53.6 | ||||||||||||||
cash-flows.row.purchases-of-investments | -129.62 | -471 | -256.2 | -637.2 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 169.72 | 391.9 | 299.2 | 615.3 | ||||||||||||||
cash-flows.row.other-investing-activites | 13.08 | 0 | 0 | -51.6 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 16.89 | -85.1 | 33 | -71.5 | ||||||||||||||
cash-flows.row.debt-repayment | -82.83 | -12 | -55.3 | -1.8 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | -7.78 | -11.1 | -9.1 | -9.8 | ||||||||||||||
cash-flows.row.other-financing-activites | 26.37 | 68.1 | 23.8 | 57 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -13.02 | 44.9 | -40.6 | 45.4 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.01 | 0.1 | -0.1 | -0.3 | ||||||||||||||
cash-flows.row.net-change-in-cash | 11.76 | -14.8 | 15.8 | -36.9 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | 68.14 | 6.8 | 21.6 | 5.8 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 56.38 | 21.6 | 5.8 | 42.7 | ||||||||||||||
cash-flows.row.operating-cash-flow | 7.88 | 25.2 | 23.6 | -10.5 | ||||||||||||||
cash-flows.row.capital-expenditure | -50.56 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.free-cash-flow | -42.68 | -7.8 | -8.1 | -62.1 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 197.21 | 274.8 | 320.3 | 269.4 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 68.14 | 88.3 | 81.4 | 60.2 | ||||||||||||||
income-statement-row.row.gross-profit | 129.06 | 186.5 | 238.9 | 209.3 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 8.41 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 78.53 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 80.37 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 0.42 | 63.2 | 69 | 69.7 | ||||||||||||||
income-statement-row.row.operating-expenses | 220.79 | 215.8 | 282.7 | 264.6 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 288.93 | 304.1 | 364.1 | 324.8 | ||||||||||||||
income-statement-row.row.interest-income | 7.65 | 0.1 | 0.1 | 0.1 | ||||||||||||||
income-statement-row.row.interest-expense | 4.83 | 11.2 | 9 | 10 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 80.37 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | -58.06 | 15.6 | 2 | -25.6 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 0.42 | 63.2 | 69 | 69.7 | ||||||||||||||
income-statement-row.row.total-operating-expenses | -58.06 | 15.6 | 2 | -25.6 | ||||||||||||||
income-statement-row.row.interest-expense | 4.83 | 11.2 | 9 | 10 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | 32.98 | 57.5 | 54.3 | 57.1 | ||||||||||||||
income-statement-row.row.ebitda-caps | 3.78 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | -29.2 | -24.5 | -42.3 | -53.2 | ||||||||||||||
income-statement-row.row.income-before-tax | -87.26 | -8.9 | -40.4 | -78.8 | ||||||||||||||
income-statement-row.row.income-tax-expense | -10.59 | -0.4 | 0.4 | 1.2 | ||||||||||||||
income-statement-row.row.net-income | -63.99 | -8.5 | -40.8 | -79.9 |
Често задавани въпроси
Какво е Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) общи активи?
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) общите активи са 911018789.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 96442814.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -0.095.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -0.095.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.004.
Какъв е общият приход на предприятието?
Общият приход е -0.050.
Каква е Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е -8496001.960.
Какъв е общият дълг на фирмата?
Общият дълг е 205303152.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 215787255.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 17684279.000.